Penny-Wise Payment for Generics
This article was originally published in RPM Report
Executive Summary
Congress is cutting what the Medicaid program will pay pharmacies for generic prescriptions. Big chains warn that could mean they use brands more.
You may also be interested in...
Here's a Switch: Pharmacies Prepare to Push Brands First in Medicaid
Pfizer's Lipitor is taking a beating as payors push use of generic statins wherever possible. But Lipitor and many other blockbuster brands may get some unexpected relief when Medicaid changes its payment rules for generics next year.
Here's a Switch: Pharmacies Prepare to Push Brands First in Medicaid
Pfizer's Lipitor is taking a beating as payors push use of generic statins wherever possible. But Lipitor and many other blockbuster brands may get some unexpected relief when Medicaid changes its payment rules for generics next year.
Reinventing Pharmacy: The Bidding for Caremark is Just the Beginning
The battle between CVS and Express Scripts for ownership of Caremark has made little impact on drug-company executives. But there is an important implication for pricing in the Medicare Part D world: CVS wants to use Caremark to help it get higher payments for providing pharmacy services. But in the zero-sum game of reimbursement, any additional profits for chains will likely come from reduced prices on drugs.